By VETTAPHARMA reporter – Derek Roche: AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) received US approval for first‑line treatment of adult patients with unresectable or metastatic triple‑negative breast cancer (TNBC) who are not candidates for PD‑1/PD‑L1 inhibitor therapy. The approval follows Priority Review by the FDA and is grounded on results from the TROPION‑Breast02 Phase III trial.
TROPION‑Breast02 enrolled 644 patients and compared Datroway with investigator’s‑choice chemotherapy (paclitaxel, nab‑paclitaxel, capecitabine, carboplatin or eribulin) in previously untreated metastatic TNBC where immunotherapy was not an option. The trial’s dual primary endpoints were progression‑free survival (PFS) by blinded independent central review and overall survival (OS).
Key efficacy outcomes showed a median OS improvement of 5.0 months with Datroway versus chemotherapy (hazard ratio 0.79; 95% CI 0.64–0.98; p=0.0290). Datroway also produced a 43% reduction in risk of progression or death (PFS hazard ratio 0.57; 95% CI 0.47–0.69; p<0.0001) and an objective response rate of 64% versus 30% for chemotherapy. The safety profile reported in the filing was described as consistent with prior Datroway trials.
Datroway is a TROP2‑directed DXd antibody‑drug conjugate (ADC) developed under the AstraZeneca–Daiichi Sankyo collaboration. The Phase III OS benefit positions Datroway to displace chemotherapy in a defined first‑line TNBC population and supports broader development across tumour types and settings; the programme includes more than 20 trials, with multiple Phase III studies ongoing in lung and breast cancer. Regulatory reviews are proceeding internationally under Project Orbis, with concurrent reviews in Australia, Canada, Singapore and Switzerland and additional submissions planned in the EU, China and Japan. The agent has been incorporated into the NCCN Guidelines as a Category 1 preferred first‑line option for metastatic TNBC patients who are not immunotherapy candidates.
For patients, the approval offers a targeted, non‑immunotherapy first‑line option with a measurable OS benefit and higher response rates compared with standard chemotherapy, which may translate into improved disease control and treatment durability for those ineligible for PD‑1/PD‑L1 inhibitors. From a commercial perspective, the label and guideline inclusion create a pathway to rapid uptake in a sizeable patient segment, reinforcing both companies’ ADC portfolios and supporting near‑term revenue and longer‑term pipeline expansion.
